| Methods | D: parallel C: unclear B: double WD: 98/434 J: 1‐1‐0 DU: ‐/4m/‐ | |
| Participants | N: 434/336 D: mainly migraine with aura C: Ad Hoc F: 82% A: mean 42 years DU: not reported S: 99 medical practices (probably in Germany) | |
| Interventions | P: 120 mg C: Flunarizine 10 mg | |
| Outcomes | R: 105/170 vs. 104/166 (investigator global assessment 'very good' or 'good') F: 4 (sd 5) vs. 4 (4) AU: decreased in 83/170 vs. 95/166 HI: not reported AEs: 66/170 vs. 52/166 Dropouts‐AEs: not reported V: 0 | |
| Notes | Large study with high dropout rate; no intent‐to‐treat analysis | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.